IgG dimers in multidonor-derived immunoglobulins: Aspects of generation and function

Current Pharmaceutical Design

Volumn 12, Issue 2, 2006, Pages 181-190

  Gronski, Peter ^a  

^a ZLB Behring   (Germany)

Author keywords

Anti idiotypic antibodies; Crossreactivity; Hypotension; IgG dimers; ITP; IVIG

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; DIMER; FC RECEPTOR; GLUCOSE; GLYCINE; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN F(AB) FRAGMENT;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BINDING KINETICS; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CROSS REACTION; CYTOKINE RELEASE; DRUG DESIGN; DRUG FORMULATION; DRUG MEGADOSE; HUMAN; HYPOTENSION; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; NONHUMAN; PH; PLASMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RESPIRATORY BURST; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; BLOOD DONOR; CHEMISTRY; IMMUNOLOGY;

ANIMALS; BLOOD DONORS; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G;

EID: 33644858114     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775193154     Document Type: Review

References (76)

1. Behring EA, Kitasato S. Über das Zustandekommen der Diphtherie-Immunitätund der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 1890; 49: 113-4.
2. Cohn EJ, Strong LE, Hughes WL, Mulford DJ, Ashworth JN, Melin N, et al. Preparation and properties of serum and plasma proteins. IV: A system for the separation into fractions of protein and lipoprotein components of biological tissues and fluids. J Amer Chem Soc 1946; 68: 459-75.
3. Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994; 139: 159-72.
4. Finlayson JS, Armstrong BL, Young AM. Reversibility of human immunoglobulin G dimerization. Acta Radiol Suppl 1971; 310: 114-23.
5. 2 portion of IgG. Clin Exp Immunol 1980; 42: 378-86.
6. Birdsall HH, Lidsky MD, Rossen RD. Anti-Fab' antibodies in rheumatoid arthritis. Measurement of the relative quantities incorporated in soluble immune complexes in sera and supernatants from cultured peripheral blood lymphocytes. Arthritis Rheum 1983; 26: 1481-92.
7. 2 fragment of human IgG. Arthritis Rheum 1985; 28: 562-8.
8. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988; 25: 41-8.
9. Gronski P, Bauer R, Bodenbender L, Kanzy EJ, Schmidt KH, Zilg H, et al. On the nature of IgG dimers. I. Dimers in human polyclonal IgG preparations: kinetic studies. Behring Inst Mitt 1988; 82: 127-43.
10. Gronski P, Bauer R, Bodenbender L, Boland P, Diderrich G, Harthus HP, et al. On the nature of IgG dimers. II. Idiotype - anti-idiotype complexes of polyclonal and monoclonal origin: size distribution patterns and molecular geometries. Behring Inst Mitt 1988; 82: 144-53.
11. Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990; 144: 1387-95.
12. van Oss CJ. Nature of specific ligand-receptor bonds, in particular the antigen-antibody bond. J Immunoassay 2000; 21: 109-42.
13. Gronski P, Haas T, Kanzy EJ, Lang W, Roder J, Ruhwedel K, et al. Indications of neutralising anti-idiotypic antibodies and selective proteolytic fragmentation in polyclonal anti-D IgG preparations. Biologicals. 2003; 31: 191-201.
14. 2 portion of IgG. Clin Exp Immunol 1980; 42: 378-86.
15. Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974; 125C: 373-89.
16. Roux KH, Strelets L, Brekke OH, Sandlie I, Michaelsen TE. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes:a role for flexibility and geometry. J Immunol 1998; 161: 4083-90.
17. Phillips ML, Oi VT, Schumaker VN. Electron microscopic study of ring-shaped, bivalent hapten, bivalent antidansyl monoclonal antibody complexes with identical variable domains but IgG1, IgG2a and IgG2b constant domains. Mol Immunol 1990; 27: 181-90.
18. Phillips ML, Tao MH, Morrison SL, Schumaker VN. Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization. Mol Immunol. 1994; 31: 1201-10.
19. Roux HK, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol 1997; 159: 3372-82.
20. Margni RA, Borel IM. Paradoxical behavior of asymmetric IgG antibodies. Immunol Rev 1998; 163: 77-87.
21. Aalberse RC, Schurman J. IgG4 breaking the rules. Immunology 2002; 105: 9-19.
22. Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. J Immunol 2003, 170: 3134-8
23. Singer M, Berg P. Gene und Genome. Heidelberg, Berlin, New York: Spektrum Akademischer Verlag GmbH, 1992;766-72.
24. Van Regenmortel MHV. From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificity and antigen-icsites. J Immunol Methods 1998; 216: 37-48.
25. Chotia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 1987; 196: 901-17.
26. Gronski P, Schridde C, Kanzy EJ, Ruhwedel K, Simshäuser K. Analytical characterization of IgG dimers in multidonor-derived IgG preparations. I. Basics of computer-simulated dissociation kinetics. Publication in preparation.
27. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998; 76: 231-48.
28. Galon J, Robertson MW, Galinha A, Mazières N, Spagnoli R, Fridman WH, et al. Affinity of the interaction between Fc gamma receptor type III (FcγRIII) and monomeric human IgG subclasses. Role of FcγRIII glycosylation. Eur J Immunol 1997; 27: 1928-32.
29. De Haas M, Vossebeld PJM, von dem Borne, Roos D. Fcγ receptors of phagocytes. J Lab Clin Med 1995; 126: 330-41.
30. Daëron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-34.
31. Malbec O, Fridman WH, Daëron M. Negative regulation of hematopoietic cell activation and proliferation by FcγRIIB. In Immunoreceptor tyrosin-based inhibition motifs. Daëron M, Vivier E, eds. Springer-Verlag Berlin Heidelberg 1999; 13-27.
32. Katz HR. Inhibitory receptors and allergy. Curr Opin Immunol 2002; 14: 698-704.
33. Malbec O, Attal JP, Fridman WH, Daëron M. Negative regulation of mast cell proliferation by FcgammaRIIB. Mol Immunol, 2002; 38: 1295-9.
34. Tridandapani S, Siefker K, Teillaud JL, Carter JE, Wewers MD, Anderson CL. Regulated expression and inhibitory function of FcγRIIb in human monocytic cells. J Biol Chem 2002; 277: 5082-9.
35. Dower SK, Titus JA, DeLisi C, Segal DM. Mechanism of binding of multivalent immune complexes to Fc receptors. 2. Kinetics of binding. Biochemistry 1981; 20: 6335-40.
36. Segal DM, Dower SK, Titus JA. The role of non-immune IgG in controlling IgG-mediated effector functions. Mol Immunol 1983; 20: 1177-89.
37. Johansson A, Erlandsson A, Eriksson D, Ullén A, Holm P, Sundström BE, et al. Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 2002; 94: 1306-13.
38. Bleeker WK, Van Rosevelt RF, Ufkes JGR. Hypotensive effects of plasma protein fraction. The relation between prekallikrein activator, bradykinin generation, and blood pressure in an animal model. J Lab Clin Med 1982; 100: 540-7.
39. Medgyesi GA, Kovács J, Jenei B, Füst G, Merétey K. Safety aspects of intravenous immunoglobulins. Immunol Invest 1988; 17: 121-33.
40. Bleeker WK, Agterberg J, Rigter GMM, de Vries-van Rossen A, Bakker JC. An animal model for the detection of hypotensive side effects of Immunoglobulin preparations. Vox Sang 1987; 52: 281-90.
41. Bleeker WK, Teeling JL, Verhoeven AJ, Rigter GMM, Agterberg J, Tool ATJ, et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 2000; 95: 1856-61.
42. Bleeker WK, Agterberg J, Rigter GMM, van Roijen N, Bakker JC. Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model. Clin Exp Immunol 1989; 77: 338-44.
43. Wright JK, Tschopp J, Jaton JC, Engel J. Dimeric, trimeric and tetrameric complexes of immunoglobulin G fix complement. Biochem J 1980; 187: 775-780.
44. Tischenko VM. Effect of hinge region state on interaction of human IgG3 with the complement system. Biochemistry (Mosc) 2001; 66: 1352-5.
45. Mollnes TE, Hogasen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol. 1998; 48: 312-7.
46. Jenei B, Lazar G, Bartha K, Medgyesi GA. Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function). Agents Actions 1991; 32: 333-8.
47. Kroez M, Kanzy EJ, Gronski P, Dickneite G. Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals 2003; 31: 277-86.
48. Teeling JL, DeGroot ER, Eerenberg AJM. Human intavenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro. Clin Exp Immunol 1998; 114: 264-70.
49. Teeling JL, Bleeker WK, Rigter G, van Rooijen N, Kuijpers T, Hack C. Intravenous immunoglobulin preparations induce mild activation of neutrophils in vivo via triggering of macrophages: studies in a rat model. Br J Haematol 2001; 112: 1031-41.
50. Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology 6th ed. Garland Science, New York and London 2004; 43-4.
51. Nemes É, Teichman F, Roos D, Maródi L. Activation of human granulocytes by intravenous immunoglobulin preparations is mediated by FcγRII and FcγRIII receptors. Pediatr Res 2000; 47: 357-61.
52. Aukrust P, Frøland SS, Liabakk NB, Müller F, Nordøy I, Haug C, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84: 2136-43.
53. Sharief MK, Ingram DA, Swash M, Thompson EJ. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 1999; 52: 1833-8.
54. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatela MA. The neutrophil as a cellular source of chemokines. Immunol Rev 2000; 177: 195-203.
55. Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol 2001; 21: 193-9.
56. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
57. Beardsley DS, Ertem M. Platelet autoantibodies in immune thrombocytopenic purpura. Transfus Sci 1998; 19: 237-44.
58. Semple JW, Lazarus AH, Freedman J. The cellular immunology associated with autoimmune thrombocytopenic purpura: an update. Transfus Sci 1998; 19: 245-51.
59. Garvey B. Management of autoimmune thrombocytopenic purpura (ITP) in adults. Transfus Sci 1998; 19: 269-77.
60. Lazarus AH, Freedman J, Semple JW. Intravenous immunoglobulin and anti-D in idiotypic thrombocytopenic purpura (ITP): mechanism of action. Transfus Sci 1998; 19: 289-94.
61. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JGJ, Hack CE, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98: 1095-9.
62. Dickneite G, Kanzy EJ. Experiments are performed according to the methodology described in reference [47].
63. Lories RJ, Casteels-Van Daele M, Ceuppens JL, Van Gool SW. Polyclonal immunoglobulins for intravenous use induce interleukin 10 release in vivo and in vitro. Ann Rheum Dis 2004; 63: 747-8.
64. Huizinga TW, Kerst M, Nuyens JH, Vlug A, von dem Borne AE, Roos D, et al. Binding characteristics of dimeric IgG subclass complexes to hu neutrophils. J Immunol 1989; 142: 2359-64.
65. Human normal immunoglobulin for intravenous administration. European Pharmacopoeia, 5th ed., 2005; volume 2: 1744-5.
66. Lacroix-Desmazes S, Misra N, Bayry J, Artaud C, Drayton B, Kaveri SV, et al. Pathophysiology of inhibitors to factor VIII in patients with haemophilia A. Haemophilia 2002; 8: 273-9.
67. Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, Muothon L. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. Biodrugs 2002; 16: 47-55.
68. Kazatchkine MD. Lecture on the occasion of a scientific meeting held in the Paul-Ehrlich-Institute in Langen/Germany on November 24, 2001.
69. Reynolds JA. Interaction of divalent antibody with cell surface antigens. Biochemistry 1979; 18: 264-9.
70. Donjerkovic D, Scott DW. Activation-induced cell death in B lymphocytes. Cell Res 2000; 10: 179-92.
71. Shen L, Lang ML, Wade WF. The ins and outs of getting in: structures and signals that enhance BCR or Fc receptor-mediated antigen presentation. Immunopharmacology 2000; 49: 227-40.
72. Sinclair NRSTC. Fc-signalling in the modulation of immune responses by passive antibody. Scand J Immunol 2001; 53: 322-30.
73. Rabinovitch N, Gelfand EW. Expression of functional activating and inhibitory Fcγ receptors on human B cells. Int Arch Allergy Immunol 2004; 133: 285-94.
74. Aktas O, Zipp F. Regulation of self-reactive T cells by human immunoglobulins - implications for multiple sclerosis therapy. Curr Pharm Design 2003; 9(3): 245-56.
75. Ciampolillo A, Guastamacchia E, Amati L, Magrone T, Munno I, Jirillo E, et al. Modifications of the immune responsiveness in patients with autoimmune thyroiditis: evidence for a systemic immune alteration. Curr Pharm Design 2003; 9(24): 1946-50.
76. Stahl D, Sibrowski W. Regulation of the immune response by natural IgM: lessons from warm autoimmune hemolytic anemia. Curr Pharm Design 2003; 9(23): 1871-80.